Journal Article

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

Ruane, Peter, Colson, Amy E, Tebas, Pablo, Saag, Michael, Towner, William J, Baden, Rachel P, Workowski, Kimberly, McHutchison, John G, Gane, Edward, German, Polina, Sax, Paul E, Yang, Jenny C, Cooper, Curtis, Dvory-Sobol, Hadas, Luetkemeyer, Anne, Marks, Kristen, Wong, David K, Stamm, Luisa M, Ni, Liyun, Morales-Ramirez, Javier O, Santana-Bagur, Jorge, Stedman, Catherine A.M, Bräu, Norbert, Sulkowski, Mark, Jayaweera, Dushyantha, Pang, Phillip S, Naggie, Susanna, Dieterich, Douglas

2015

Overview

Among patients coinfected with HIV-1 and HCV genotype 1 or 4 who were receiving effective antiretroviral therapy, treatment with 12 weeks of ledipasvir and sofosbuvir was associated with a sustained HCV virologic response in 96% of patients. Globally, an estimated 4 million to 5 million persons are chronically infected with both human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV). 1 Patients who are coinfected with HIV-1 and HCV have higher rates of cirrhosis, hepatocellular carcinoma, and hepatic decompensation than do patients monoinfected with HCV; they also have a higher rate of death from any cause. 2 – 8 In observational cohort studies, treatment-induced clearance of HCV infection has been associated with decreased morbidity and mortality associated with liver disease. 9 , 10 However, treatment of HCV with interferon and ribavirin in patients who are coinfected with HIV-1 and HCV . . .

• Publisher: Massachusetts Medical Society
• Subject: Anti-Retroviral Agents - therapeutic use / Antiretroviral drugs / Antiviral Agents - adverse effects / Antiviral Agents - therapeutic use / Antiviral drugs / Benzimidazoles - adverse effects / Benzimidazoles - pharmacokinetics / Benzimidazoles - therapeutic use / Cirrhosis / Diarrhea / Drug Resistance, Viral / Drug therapy / Drug Therapy, Combination / Efavirenz / Emtricitabine / Fatigue / Female / Fluorenes - adverse effects / Fluorenes - pharmacokinetics / Fluorenes - therapeutic use / Genotype / Genotype & phenotype / Genotypes / Headache / Hepacivirus - drug effects / Hepacivirus - genetics / Hepacivirus - isolation & purification / Hepatitis / Hepatitis C / Hepatitis C, Chronic - complications / Hepatitis C, Chronic - drug therapy / HIV / HIV Infections - complications / HIV Infections - drug therapy / HIV-1 / Human immunodeficiency virus / Humans / Inhibitor drugs / Liver cirrhosis / Male / Middle Aged / Patients / RNA, Viral - blood / Sofosbuvir / Tenofovir / Uridine Monophosphate - adverse effects / Uridine Monophosphate - analogs & derivatives / Uridine Monophosphate - pharmacokinetics / Uridine Monophosphate - therapeutic use / Viral Load